Yan Jin, Zhou Xiaoying, Dang Yini, Yin Chengqiang, Zhang Guoxin
Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China; The First School of Clinical Medicine of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Mol Clin Oncol. 2016 Jan;4(1):100-106. doi: 10.3892/mco.2015.657. Epub 2015 Oct 16.
Several studies have investigated the correlation between the expression of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and cancer prognosis, with inconsistent results. Therefore, a meta-analysis was conducted to identify the potential correlation after pooling data from eligible studies. PubMed/Medline, Web of Science and The Cochrane Library electronic databases were searched for eligible studies on the prognostic role of MALAT1 in cancer, from inception to January, 2015. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to summarize the effect. A total of 1,198 patients from 10 studies were included in the analysis. The results suggested that MALAT1 expression was significantly associated with overall survival (HR=2.07, 95% CI: 1.67-2.56), disease-free survival (HR=2.60, 95% CI: 1.69-4.00) and recurrence-free survival (HR=3.28, 95% CI: 1.52-7.09). MALAT1 was also found to be significantly associated with tumor size (P=0.013). Overall, MALAT1 expression may be considered as a potential prognostic factor for cancer patients.
多项研究调查了转移相关的肺腺癌转录本1（MALAT1）表达与癌症预后之间的相关性，结果并不一致。因此，进行了一项荟萃分析，以汇总符合条件的研究数据后确定潜在的相关性。检索了PubMed/Medline、Web of Science和Cochrane图书馆电子数据库，以查找从开始到2015年1月关于MALAT1在癌症中预后作用的符合条件的研究。计算合并风险比（HR）及95%置信区间（CI）以总结效应。分析共纳入了来自10项研究的1198例患者。结果表明，MALAT1表达与总生存期（HR=2.07，95%CI：1.67-2.56）、无病生存期（HR=2.60，95%CI：1.69-4.00）和无复发生存期（HR=3.28，95%CI：1.52-7.09）显著相关。还发现MALAT1与肿瘤大小显著相关（P=0.013）。总体而言，MALAT1表达可被视为癌症患者的一个潜在预后因素。
